We used qRT-PCR methodology to detect the expression of four TP53 target genes (PUMA, BAX, CDKN1A, CDKN2A) and their expression was evaluated on paired tumor and margin samples from 21 OSCC patients. This evidence concerns the gene CDKN2A and neoplasm.